Cohorte de nacimiento de precisión de Westlake (WeBirth)
The Westlake Precision Birth Cohort (WeBirth) is a prospective cohort study among women with hyperglycemia during pregnancy and their offspring living in Hangzhou, China. The primary aim of this cohort is to characterize the continuous blood glucose response to dietary intake and physical activity among pregnant women with gestational diabetes mellitus (GDM) over 2 weeks, and to facilitate the development of personalized nutritional/lifestyle recommendation among these patients. Another aim of WeBirth is to investigate the association of dietary intake and physical activity together with continuous glucose change during pregnancy on the adverse birth outcomes including preterm birth, macrosomia and large-for-gestational-age birth. The secondary aim is to investigate the prospective associations of diet, physical activity and continuous glucose change over 2 weeks among the participants with long-term metabolic health of these women and their offspring.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
In China, an alarming increase in the prevalence of GDM has been observed in the past decade. GDM is of concern because it is associated with several maternal and fetal medical disorders. Lifestyle changes such as diet and physical activity modifications are key for the prevention and treatment of GDM. However, the associations between dietary intake and physical activity and health outcomes for GDM women and their children remain unclear due to subjective measurements of diet and physical activity. Recently, the development of objective measurements such as food image identification and wearable activity trackers give an opportunity to gain more precise insight into these associations. In addition, for the same food and physical activity exposures, GDM women may have different blood glucose responses, but the nature of variation is currently poorly characterized. Therefore, the present WeBirth design incorporates three unique components, 1) objective measurement of physical activity during pregnancy using accelerometer; 2) measurement of dietary intake using both the Food Frequency Questionnaire and dietary records; 3) measurement of blood glucose levels over 2 weeks using continuous glucose monitors, with three standardized test meals during the 2 weeks. We will then follow up these women participants during and after this pregnancy, and also follow up their offspring.
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Zhejiang
-
Hangzhou, Zhejiang, Porcelana, 310030
- Hangzhou Women's Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Women aged 18 years or older
- Women with GDM at 24-28 weeks of gestation
- Women intended to deliver at Hangzhou Women's Hospital
- Women intended to remain in Hangzhou with their child for ≥4 years
Exclusion Criteria:
● Women with cancer and other serious medical disorders
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Otro: Standardized breakfast
Egg (50g), whole-wheat bread (35g), celery (30g), and dried bean curd (10g) |
Participants will be provided with a standardized breakfast on a morning of the days they wear a continuous glucose monitoring (CGM) device. |
|
Otro: Standardized snack
Tomato (50g) and skim milk (200g) |
Participants will be provided with a standardized snack 2 hour after they have the standardized breakfast. |
|
Otro: Standardized lunch
Rice (40g), oats (40g), shrimp (70g), lettuce (80g), lean pork (30g), carrot (10g), soaked auricularia auricula (20g), broccoli (80g), cucumber (10g), tomato egg drop soup (200g), salt (3g), and oil (8g) |
Participants will be provided with a standardized lunch 2 h after they have the standardized snack. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Continuous blood glucose change over 2 weeks
Periodo de tiempo: Two weeks after enrollment
|
Glucose levels are assessed by continuous glucose monitoring over 2 weeks. |
Two weeks after enrollment
|
|
Adverse birth outcomes
Periodo de tiempo: 9-12 weeks after enrollment
|
Number of participants with adverse birth outcomes, such as, preterm birth, macrosomia and neonatal hypoglycemia. |
9-12 weeks after enrollment
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Body fat of the maternal participants
Periodo de tiempo: 6 months and 3 years after delivery
|
Body fat is assessed by the equipment of dual-emission X-ray absorptiometry (DXA) for the mothers. |
6 months and 3 years after delivery
|
|
Weight changes of the children during early childhood
Periodo de tiempo: at delivery, age of 6 months, 1 year, 3 years and 6 years
|
Weight in kilograms |
at delivery, age of 6 months, 1 year, 3 years and 6 years
|
|
Number of participants developing type 2 diabetes
Periodo de tiempo: 6 years and 10 years after delivery
|
Risk of developing type 2 diabetes after the delivery of the women with gestational diabetes. |
6 years and 10 years after delivery
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Ju-Sheng Zheng, PhD, Westlake University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades del sistema endocrino
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Enfermedades metabólicas
- Complicaciones del embarazo
- Trastornos del metabolismo de la glucosa
- Diabetes mellitus
- Enfermedades Nutricionales y Metabólicas
- Diabetes Gestacional
- Embarazo en diabéticos
Otros números de identificación del estudio
Otros números de identificación del estudio
- 20190701ZJS0007
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .